Exciting Clinical Trials Opportunities with masitinib in dogs

We are excited to offer inclusions in 6 open label clinical studies with masitinib oral route in the following indications:

Indication	Treatment	Allocation	Frequency of visits
All cancers	Combination masitinib/vinblastin	Single arm study	Every week
All cancers	Combination masitinib/gemcitabin	Single arm study	Every week
Splenic hemangiosarcoma (dogs naïve of treatment)	Masitinib Doxorubicin Combination masitinib/doxorubicin	Automatic randomization	Every 3 weeks
T cell lymphoma (dogs naïve of treatment)	Masitinib Doxorubicin Combination masitinib/doxorubicin	Automatic randomization	Every 3 weeks
Melanoma (dogs naïve of treatment)	Combination masitinib/doxorubicin Vaccine	Automatic randomization	Every 3 weeks Every 2 weeks
Melanoma expressing mutated c-kit (dogs naïve of treatment)	Masitinib Vaccine	Automatic randomization	Every 2 weeks

Masitinib is a registered therapy in Europe to treat unresectable Mast Cell Tumors in dogs. Masitinib is a Tyrosine Kinase Inhibitor that selectively inhibits c-kit, PDGFr and Lyn.
Main exclusion criteria are: Dogs less than 6 months of age or weighing less than 3.5 kg (7.7 lb), with cardiac insufficiency, evidence of gastric bleeding, other serious disease or prior history of kidney disease.

Rationale for the use of masitinib as single therapy:

Masitinib inhibits proliferation of mast cells (via c-kit inhibition) that play a role in tumors growth, the metastatic process and immunosuppression. Also inhibition of the Lyn/FAK signaling pathway may impede development of chemoresistance and metastasis.



Masitinib strongly inhibits the proliferation of T-cell lymphoma cell lines (through PDGFr inhibition).



Rationale for combination of masitinib with chemotherapy:

In vitro, Masitinib strongly sensitizes several cancer cell lines to chemotherapy (including hemangiosarcoma, T cell lymphoma and melanoma cancer cell lines).



AB SCIENCE

The studies are partially funded. For more details, please contact Maria Salas or Dr. Gerald Post at 203-838-6626